ESC Premium Access

State of the Art - Metabolic aspects of vascular disease

Congress Session

About the speaker

Professor Massimo Federici

University of Rome Tor Vergata, Roma (Italy)
1 presentation
0 follower

4 more presentations in this session

Role of the gut microbiome for the cholesterol lowering effect of atorvastatin

Speaker: Miss F. Zimmermann (Berlin, DE)


Identification of celastramycin as a novel therapeutic agent for pulmonary arterial hypertension -high-throughput screening of 5,562 compounds-

Speaker: Doctor R. Kurosawa (Sendai, JP)


The SGLT2 inhibitor empagliflozin reduces mortality in experimental pulmonary hypertension

Speaker: Professor S. Verma (Toronto, CA)


Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury

Speaker: Professor R. Touyz (Montreal, CA)


Access the full session

Novel pharmacological targets in vascular disease

Speakers: Professor M. Federici, Miss F. Zimmermann, Doctor R. Kurosawa, Professor S. Verma, Professor R. Touyz

About the event



31 August - 4 September 2019

Sessions Presentations

Related content

Open Access

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - panel.

30 August 2021

Open Access

Management of ASCVD risk in people with diabetes mellitus.

30 August 2021

Open Access

Introduction, novel concepts in the 2021 ESC Prevention Guideline.

30 August 2021

This platform is supported by

logo Novo Nordisk